ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

ZVRA Zevra Therapeutics Inc

4,82
0,02 (0,42%)
15 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Zevra Therapeutics Inc ZVRA NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,02 0,42% 4,82 23:59:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
4,90 4,81 4,97 4,82 4,80
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
13.5.202422:47EDGAR2Form 8-K - Current report
09.5.202422:34EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09.5.202413:30GLOBEZevra Therapeutics to Participate at Upcoming Investor..
08.5.202413:54EDGAR2Form 8-K - Current report
08.5.202413:00GLOBEZevra Therapeutics Reports First Quarter 2024 Financial..
01.5.202413:30GLOBEZevra Therapeutics to Report First Quarter 2024 Results on..
29.4.202413:30GLOBEZevra Therapeutics’ President and Chief Executive Officer..
15.4.202423:01GLOBEZevra Therapeutics Presents New Data on the Long-Term Safety..
10.4.202413:30GLOBEZevra Therapeutics Refinances Existing Debt with up to $100M..
28.3.202421:32GLOBEZevra Therapeutics Reports Fourth Quarter and Full Year 2023..
28.3.202412:42IHMARKETNEWSUS Stock Futures Stable in Pre-Market On Path for..
26.3.202421:30GLOBEZevra Therapeutics Announces Top-Line Data from the Phase 2..
25.3.202421:30GLOBEZevra Therapeutics to Present at the 23rd Annual Needham..
18.3.202412:30GLOBEZevra Therapeutics to Report 2023 Fourth Quarter and Full..
05.3.202413:34EDGAR2Form 8-K - Current report
04.3.202414:24EDGAR2Form 8-K - Current report
04.3.202413:30GLOBEZevra Therapeutics Provides FDA Update on the PDUFA Action..
28.2.202413:30GLOBEZevra Therapeutics to Participate at Upcoming Investor..
14.2.202422:51EDGAR2Form SC 13G - Statement of acquisition of beneficial..
06.2.202413:30GLOBEZevra Therapeutics to Present at the Oppenheimer 34th Annual..
03.2.202403:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.2.202402:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.2.202402:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.2.202402:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.2.202402:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.2.202402:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.2.202402:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02.2.202413:13EDGAR2Form 3 - Initial statement of beneficial ownership of..
23.1.202413:37EDGAR2Form 8-K - Current report
23.1.202413:30GLOBEZevra Therapeutics Appoints Experienced Biopharma Executive..
11.1.202422:50DJNXoma to Make $1 Million Milestone Payment to LadRx After FDA..
08.1.202414:03EDGAR2Form 8-K - Current report
08.1.202413:30GLOBEZevra Therapeutics Receives FDA Acceptance of Resubmission..
04.1.202414:55GLOBEZevra Therapeutics Appoints Global Medical Leader, Adrian..
27.12.202314:24DJNZevra Therapeutics Refiles Arimoclomol Application With FDA
27.12.202313:48EDGAR2Form 8-K - Current report
27.12.202313:30GLOBEZevra Therapeutics Announces Resubmission of Arimoclomol New..
20.11.202313:36EDGAR2Form 8-K - Current report
20.11.202313:30GLOBEZevra Therapeutics Completes Acquisition of Acer..
07.11.202323:23EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07.11.202313:25EDGAR2Form 8-K - Current report
07.11.202313:00GLOBEZevra Therapeutics Reports Corporate Updates and Third..
31.10.202312:30GLOBEZevra Therapeutics to Report Third Quarter 2023 Results on..
30.10.202321:42EDGAR2Form 425 - Prospectuses and communications, business..
30.10.202313:25EDGAR2Form 8-K - Current report
19.10.202313:30GLOBEZevra Therapeutics Celebrates and Supports Global..
11.10.202322:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11.10.202306:15EDGAR2Form EFFECT - Notice of Effectiveness
11.10.202302:20EDGAR2Form 3 - Initial statement of beneficial ownership of..
10.10.202323:12EDGAR2Form 8-K - Current report